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For over two hundred years there has been documentation 
of the extreme concern and quest for a method to restrain 
cancer, a condition which has plagued both men and animals 
(Karnofsky, 1948). The primary obstruction to the control 
and eradication of this class of disease has been the lack of 
a thorough understanding of the mechanisms involved in neo-
plastic establishment, survival, and growth, although the 
presence of tumor-specific transplantation antigens and an 
immunocompetent host has been established (Smith, 1975). 
A number of workers have observed the existence of a 
fibrin investment early in the development of implanted and 
spontaneously arising tumors (Hiramoto, 1960; Dvorak, 1979). 
As early as 1878, Billroth detected tumor cells encased 
inside a fibrin deposit (Zacharski, 1979). Tumors have been 
observed to possess the ability to stimulate the prolifera-
tion of host vessels to meet their metabolic needs in a 
number of clinical and experimental systems including man, 
mice, rats, and rabbits (Gimbrone, 1974; Folkman, 1975, 1976; 
Auerbach, 1976; Gullino, 1978; Chodak, 1980). Studies exam-
ining the vascularization of tumors have confirmed tumor 
growth dependence upon a vascular supply (Folkman, 1976; 
Gullino, 1981). Experiments in which the tumor is physically 
separated from other tissues demonstrate the tumor is still 
l 
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capable of stimulating vascular proliferation through the 
barrier--supporting the theory that tumor cells release a 
diffusible tumor angiogenesis factor (Folkman, 1976). The 
isolated tumor angiogenesis factor has mitogenic effects 
upon capillary endothelial cells and can cause the formation 
of tubular networks of blood vessel endothelial cells in 
vitro (Folkman, 1980). Although a vast amount of research 
has been conducted in this area, numerous questions still 
exist in the understanding of the relationship of tumor 
establishment and growth. 
RATIONALE 
Previous experiments in the laboratory under the direc-
tion of Dr. Katherine K. Knapp looked at the effects of 
sodium heparin upon the growth and morphology of implanted 
spontaneous C3HjHeJ mouse mammary tumors. These experiments 
demonstrated that heparin anticoagulation was accompanied by 
reduced tumor growth and vascularization (Knapp et al., 
1981). The concept of tumor dependence upon angiogenesis 
for growth has led to the proposal that a heparin-induced 
alteration in the host's normal blood coagulation pathway 
could modulate fibrin encasement of the tumor and circumvent 
its establishment. This was thought to be a~complished 
through a reduction in tumor vascularization as a result of 
the decreased fibrin encasement of the tumor (Knapp et al., 
1981; Banaja, 1982). 
Continuing the study of the relationships between 
fibrin investment of the tumor, vascularity, and tumor 
growth, we decided to investigate the relationship of war-
farin sodium anticoagulation with tumor growth and vascu-
larization. It was reasoned that if the previously observed 
altered tumor growth was due to heparin's anticoagulant 
effect rather than a direct effect upon the tumor, another 
anticoagulant with a different mechanism of action would 
have the same tumor growth reducing capabilities. Warfarin 
sodium produces reduced fibrin pqlymer formation by a 
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mechanism entirely different from that of heparin. Hepar~n's 
immediate anticoagulant activity results from a blockade of 
thrombin's activity on fibrinogen, prevention of prothrombin 
conversion to thrombin, and a reduction in platelet adhe-
siveness (Vigran, 1965; Gilman, 1980). Warfarin's delayed 
activity, however, is through an inhibition of vitamin K 
activity leading to reduced synthesis of several clotting 
factors (Gilman, 1980). With the decision to use warfarin 
sodium, experiments were designed to test the hypothesis 
that a reduction or prevention of fibrin formation and thus 
tumor encasement with this polymer would alter tumor growth. 
It was also hypothesized that, accompanying the altered 
tumor growth, several macroscopic factors including tumor 
vascularization, extent of tumor attachment, vasodilation 
of host blood vessels in the locale of the implanted tumor, 
and local edema fluid would be altered. Experiments were 
conducted to determine the relationship between the dose 
of warfarin sodium administered and the degree of alteration 
of tumor growth and the related factors. An inverse dose-
response relationship between dose of warfarin and tumor 
growth and the related parameters was hypothesized. 
LITERATURE SURVEY 
Studies of Dvorak 
Part of the foundation for our studies developed from 
investigations conducted by Harold Dvorak and his associates 
at Harvard University Medical School. Using line 10 guinea 
pig hepatocarcinoma and relying upon his observations from 
these studies, Dvorak postulated that a tumor has the 
capacity to promote its growth through the manipulation of 
its host's clotting system (1979, 1979a). Dvorak demon-
strated that the tumor cells released four factors which 
have the capacity to effectively alter the host's immune and 
infla~matory mechanisms. These alterations entail an 
increase in vascular permea~ility in the tumor locale, stim-
ulation of blood coagulation, a stimulatory effect upon 
plasminogen and inhibition of macrophage migration (Dvorak, 
1979, 1979a). 
The first factor distinguished was the vascular permea-
bility factor (Dvorak, 1979, 1979a). This factor was postu-
lated to contribute to the tumor's establishment of a fibrin 
encasement by permitting the escape of plasma and thus 
clotting factors into the area of the tumor (Dvorak, 1979, 
1979a). Its activity has been thought to be upon the capil-
lary endothelial cells (Dvorak, 1979, 1979a). Further inves-
tigations demonstrated that this factor is not histamine. 
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Prophylactic treatment with antihistamine showed a reduction 
of vascular permeability, but the treatment possessed no 
suppressive effects upon the tumor-released vascular permea-
bility actions (Dvorak, 1979). A tumor-released second 
factor was identified as a procoagulation factor (Dvorak, 
1979, 1979a). Dvorak proposed that this factor also plays 
a vital role in fibrin deposition around the tumor by poten-
tiating thrombus formation, and by activating the clotting 
factors which had migrated into the tumor area by virtue of 
increased vascular permeability (Dvorak, 1979, 1979a). The 
third factor promoting tumor growth was a plasminogen acti-
vator (Dvorak, 1979, l979a). This factor, Dvorak pointed 
out, has been found to be associated with many malignant 
cell types (1979). It has been suggested that the plasmino-
gen activating factor may serve as a useful feature in 
invasion as a nonspecific protease (Dvorak, 1979). The 
third proposed activity of this factor was one of fibrino-
lytic activity for cocoon breakdown providing room for tumor 
growth (Dvorak, 1979). The fourth factor demonstrated by 
Dvorak was a macrophage migration inhibition factor (1979, 
1979a). It is suggested that this tumor-mediated inhibitory 
action may aid in the tumor's ability to block the host's 
immunologic response and ultimate tumor destruction by 
achieving a depression of macrophage migration to the area 
of neoplastic development (Snyderman et al., 1976; Dvorak, 
1979). This factor has been explored in several other assays 
along with those conducted by Dvorak and Snyderman (Green et 
al., 1977). Suggestions have been made that these four 
mediators set the groundwork for a dynamic process of a 
continuing reconstruction of the fibrin encasement, facili-
tating tumor growth (Figure I). 
More recent studies have presented new evidence sup-
porting Dvorak's procoagulant factor postulate. Studies of 
carcinomas in guinea pigs and mice have shown that these 
carcinomas shed plasma membrane vesicles when cultured in 
vivo or in vitro. Dvorak reported that the vesicles con-
tained procoagulant and attributed the fibrin encasement 
found around the carcinomas to the procoagulant produced 
(Dvorak et al., 1981). 
Tumor and C3HjHeJ Strain 
7 
While developing the protocol, it was decided that a 
spontaneous tumor should be the source of the tumor implants. 
Chemically-induced, virally-induced and passaged tumors are 
known to differ from spontaneously developed tumors both 
in the antigens exhibited on their surfaces and in their 
growth rates (Robbins, Angell, and Kumar, 1981). Those 
tumors which are chemically induced exhibit a heterogeneous 
population of tumor-specific transplantation antigens on 
their surfaces (Foulds, 1975). Virally-induced tumors 
associated with DNA or RNA viruses, display a homogeneous 
population of tumor-specific transplantation antigens on 
their cells' surfaces (Busch, 1974; Robbins, Angell, and 
Kumar, 1981). Yet, those tumors which arise spontaneously 
demonstrate very few transplantation antigens. Likewise, 
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those tumors which frre continuously passaged grow much more 
rapidly than spontaneous tumors (Robbins, Angell, and Kumar, 
1981; Becker, 1977; Koller, 1960). Thus, it appears that 
those tumors which are not spontaneous in origin may be dif-
ferent from naturally developing tumors in· terms of growth 
and host immune response. Spontaneous tumors are therefore 
preferred for research when clinical correlations are to be 
suggested. 
Mouse mammary tumors are widely used models for tumor 
biology study (Greene, 1966). The C3H inbred strain of 
mice originated from a cross by Strong in 1920 of Bagg 
albino mice and DBA strains of mice. The strain was ex-
changed to Andervont in 1930 and exchanged again to Heston 
in 1938 at F35. The colony remained with Heston until 1947 
when Jackson took over the colony at F48 (Inbred Strains of 
Mice No. 10, July 1977; No. 4, July 1965). C3HjHeJ female 
mice exhibit a high incidence of spontaneously arising mam-
mary tumors. A 65 percent incidence of manrnary tumors is 
reported in breeding females at age 6 months, while a some-
what lower incidence of 28 percent is observed in virgin 
females at age 6 months (personal communication, Jackson 
Laboratory, Bar Harbor, Maine). The C3HjHeJ males have a 
tendency to develop hepatomas and both sexes have relatively 
low red and white cell counts (Inbred Strains of Mice, 
No. 10, July 1973; Comp. to No. 57, July, 1977). Breeding 
statistics on the C3H/HeJ mouse report a breeding performance 
in 1970 animals of 95 percent fertility with 4.2 litters per 
fertile dam, and an average litter size of 6.2 (Inbred 
Strains, #6, Comp. No. 41, July 1969; No. 5, July 1967). 
Fundamental Attributes of Neoplasia 
In Pathophysiology: The Biological Principles of 
11 
Disease, HenryS. Kaplan defined cancer as a". generic 
category of disease . " emphasizing that although neo-
plastic g+owth is found in variable locations and cancer has 
a variety of ways of expressing itself, there are fundamental 
characteristics expressed which are unique to cancer cells 
(Smith and Thier, 1981). It is widely recognized that any 
cell which belongs to a dividing cell population has tpe 
potential to transform into a cancer cell (Smith and Thier, 
1981). Numerous studies have also supported the principle 
that a cancerous mass results from the growth of one trans-
formed cell (Isselbacher et al., 1980; Robbins, Angell and 
Kumar, 1981; Smith and Thier, 1981). Another major charac-
teristic commonly associated with tumor growth is the absence 
of response to mechanisms controlling growth. A neoplasm 
does not necessarily grow more rapidly, a common misconcep-
tion, but it simply does not stop expanding provided it 
can meet its metabolic needs (Robbins, Angell, and Kumar, 
1981). Robbins, Angell and Kumar also point out that the 
capacity for transplantation, the ability to grow in culture 
without an anchorage, and the absence of contact inhibition 
are relatively less common in normal cells which have not 
undergone transformation (1981). Investigations have also 
demonstrated that the biochemical changes associated with 
most cancer cells are linked to the degree of the cancer 
cell differentiation. Those less differentiated cells 
usually demonstrate characteristics which greatly deviate 
from those of the normal cell population from which the 
transformed cells arose (Robbins, Angell and Kumar, 1981). 
Cells which are more differentiated are found to resemble 
the biochemical nature of the cells of origin more closely 
(Robbins, Angell and Kumar, "1981). 
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Another characteristic which is extremely important in 
reviewing the features of neoplasia is invasiveness, typical 
of all malignant tumors (Smith and Thier, 1981). This 
property is not necessarily accompanied by metastasis. Inva-
siveness is the major property causing concern because it 
permits the dissemination of malignant cells outside the 
confinement of the original tumor (Smith and Thier, 1981). 
Spread can occur directly into the body cavities, by pene-
tration of the lymphatic system, or through hematogenous 
invasion (Robbins, Angell and Kumar, 1981). Thus, it is 
understandable that a large amount of interest in experimen-
tation centers around neoplastic invasiveness and metastasis. 
Tissue Transplantation 
Transplantation physiology is a topic closely associated 
with immunology. The interconnection of the two fields of 
study stems from host recognition of antigens of the trans-
planted tissue. Tumor cells possess specific antigens on 
13 
their surfaces commonly known as tumor-specific transplan-
tation antigens (Hyde and Patnode, 1978; Robbins, Angell and 
Kumar, 1981). These antigens are able to evoke an immune 
response and some immunologists support the idea that through 
immune surveillance the host is able to continuously mount 
an immune-triggered rejection of tumor cells; however, under 
~ . 
some conditions the tumor cells are able to shield themselves 
and escape elimination by the host (Hyde and Patnode, 1978; 
Smith and Thier, 1981). 
In experimental analysis employing implanted tissue, 
several rules of transplantation must be remembered. These 
guidelines include isografts and tissues derived from inbred 
strains or syngeneic animals, which are generally transplanted 
successfully (Green, 1966; Guyton, 1981). Transplants of 
allografts, or tissues originating and implanted within a 
species, usually enjoy a greatly reduced transplantation 
success rate (Green, 1966; Guyton, 1981). Green has also 
noted that transplants arising from parents of an inbred 
strain to Fl hybrids take, yet transplants from the Fl to 
the parent are not successful (Green, 1966). Clinical and 
experimental examinations have shown that the more distantly 
related the donor and host are, the greater the severity of 
the immune rejection (Guyton, 1981). Additionally, a possible 
immune response to the tumor-specific transplantation anti-
gens must be acknowledged (Robbins, Angell and Kumar, 1981). 
14 
Blood Coagulation 
Blood coagulation, under normal physiological condi-
tions, involves a cascade of linked reactions resulting in 
the activation of more than twelve clotting proteins and 
requiring the participation of platelets and calcium. These 
components ultimately lead to the formation of a stable 
fibrin clot. The clotting proteins are synthesized in the 
liver, and significant hepatic damage or vitamin K deficiency 
greatly reduces their production and consequently greatly 
influences blood coagulation (Isselbacher et al., 1980). 
The clotting mechanism is composed of two pathways, the 
intrinsic and extrinsic systems, either of which can cause 
fibrin formation. Although leading to the same final reac-
tions, the systems have cert~in distinctive characteristics. 
The intrinsic system relies solely upon clotting factors 
found within the circulating blood for its activity. Upon 
the appropriate stimulus the factors are sequentially acti-
vated leading to prothrombin conversion to thrombin which 
initiates fibrinogen conversion to fibrin. In the presence 
of factor XIII, the fibrin-stabilizing factor, a stable 
fibrin clot is formed. Unlike the intrinsic system, the 
extrinsic system is dependent upon clotting factor III, 
tissue thromboplastin, for its activation. This factor is 
not found in circulating blood. The clotting cascade reac-
tions, leading to the formation of a s·table fibrin clot, 
occur much more rapidly, within seconds as opposed to minutes, 
in the intrinsic system. This rapid progression is achieved 
15 
by skipping several reactions required in the intrinsic sys-
tern. Eventually, both pathways result in factor X activation 




Traditional categorization places the anticoagulants into 
two subdivisions. These groups include those agents with 
direct action, such as sodium heparin, and those agents with 
indirect action such as 4-hydroxycoumarin. The direct acting 
anticoagulants are termed such due to their action both in 
vivo and i.n vitro; whereas, those classified as indirectly 
acting anticoagulants exhibit only in vivo activity (Wormser, 
1978). Three-(a-phenyl-B-acetylethyl)-4-hydroxycoumarin 
sodium, more widely recognized by its generic and proprietary 
names of warfarin sodium· and coumadin (Vigran, 1965), has an 
interesting history. Over 40 years ago both scientific and 
lay observations began to accumulate which noted a relationship 
between a hemorrhagic sweet clover disease affecting livestock, 
prothrombin, the liver, and vitamin K (Vigran, 1965). Frag-
ments of evidence evolved into an understanding of the nature 
of anticoagulation which in turn led to the use of the devel-
oped soluble salt warfarin for rodenticidal purposes until 
1953. At this time Shepard Shapiro of New York suggested it 
as a clinically useful medication (Vigran, 1965). 
The coumarins exhibit no activity in vitro and only 
minimal anticoagulant activity for at least 12 to 24 hours 
Factor Name 
I Fibrinogen 
I ' Fibrin monomer 
I" Fibrin polymer 
II Prothrombin 
III Tissue Thromboplastin 
IV Ca2+, Calcium 
V Labile factor 
VII Proconvertin 
VIII Antihemolytic Globulin, AHG 
IX Christmas Factor, PTC 
X Stuart Factor 
XI Plasma Thromboplastin ante-
cedent, PTA 
XII Hageman Factor 
XIII Fibrin-Stabilizing factor 
PL Platelet Phospholipid 
Figure IT. Common Synonyms of Blood Clotting Factors 
(Modified from Gilman, 1980). 
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following the initiation of a dosing regimen (Wormser, 1978). 
Coumarin activity has been demonstrated within the liver 
cell, with evidence suggesting it lies specifically within 
the liver mitochondria enzyme systems (Vigran, 1965). Spe-
cifically, coumarin results in a hindrance of hepatic syn-
thesis of vital plasma clotting factors: II, VII, IX, X. 
This antagonism is accomplished through an inhibition or 
antagonism of vitamin K activity and.transport (Suttie, 
1979; Wormser, 1978; DeMeo, 1982). Biochemical analysis 
has shown that vitamin K is a necessary component of coagu-
lation. It serves as a coenzyme in some liver cell phosphory-
lation reactions in which coumarins effectively block the 
phosphorylation (Vigran,· 1965). Additional studies, examin-
ing the close resemblance of the chemical structures of 4-
hydroxycoumarin and vitamin K, have alluded to the possi-
bility that this similarity may be key in the anticoagulant 
activity of coumadin (Vigran, 1965), (Figures III~ IV, V, 
and VI). 
The ultimate effect of warfarin sodium administration 
is hypocoagulability. This is achieved with a sequential 
fall in plasma concentration of clotting factors VII, IX, 
X, and II. Maximum clotting factor depression does not occur 
until 24 to 58 hours after the peak plasma concentration is 
reached (Vigran, 1965). Cessation of warfarin sodium therapy 
results in a gradual return to the normal concentration of 
plasma clotting factors, with a progressive increase in 
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Figure VI. Structure and Origin of Vitamin K3 . 
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(Figures VII, VIII, and IX). In man, this phenomenon 
requires between one and two weeks (Vigran, 1965). 
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Goodman and Gilman report that in man, warfarin sodium 
is metabolized in the liver. Racemic warfarin in the circu-
lation is almost totally bound (99%) to plasma albumin during 
the long-term therapy and following i.v. bolus administration 
the half life in humans is 35 hours (O'Reilly et al., 1968; 
Gilman et al., 1980). The half life of warfarin sodium is 
quite variable among species. This variability is even seen 
between sexes in normal Sprague-Dawley rats which exhibit a 
mean plasma half life of 18 hours in males and 28 hours in 
females ( 0' Reilly et al., 1968). A few studies have been 
conducted in mice, also revealing species variability in the 
half life of warfarin sodium. In May 1974 an investigation 
of warfarin's influence upon blood coagulation by Neidner, 
Kayser, and Meyer showed that mice require ten times more 
warfarin per unit body weight to obtain the same anticoagu-
lation as in a rat (Neidner et ~1.). Neidner et al. also 
found the half life of warfarin in mice to be 4.5 hours 
(1974). In a subsequent publication Neidner investigated 
the serum protein binding of warfarin sodium in rats and 
mice and reported.the half life of this agent as 1.9 hours 
in the mouse with a cumulative LD50 of 25.0 mgjkg of warfarin 
sodium, while the half life in rats was 19.5 hours and the 
LD50 was 2.1 mgjkg (Neidner, 1974b). Personal communication 
with Gerhard Levy from the Department of Pharmaceutics, 
Scqool of Pharmacy, State University of New York at Buffalo 
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Figure VIII. Action of Warfarin Upon Thrombus Formation. 
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Figure IX. Activity of Vitamin K in Clot Formation. 
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confirms the extreme variability of warfarin's half life 
even within the same animal strains. Levy states that the 
half life of warfarin within a single strain of rats differs 
within a 30-fold range and that the half life of this agent 
relates to protein binding, but the critical protein is not 
albumin (personal communication). 
Finally, as is understood with any pharmacologic agent, 
both physiological and pathological factors can either 
increase or decrease the response to oral anticoagulant 
drugs. These factors seldom affect the kinetics of accumu-
lation of the anticoagulant drug, but they do influence the 
biological effect (Gilman et al., 1980). Coumadin has also 
been shown to demonstrate biologic actions other than anti-
coagulation. These include vasodilation, bronchodilation, 
and uricosuric effects (Vigran, 1965). O'Reilly has also 
shown that plasma warfarin, in humans, is found in an 
unchanged form and warfarin metabolites are found in the 
urine and stool (O'Reilly et al., 1968). 
Vitamin K 
Vitamin K naturally occurs as vitamins K1 in leafy green 
vegetables and as vitamin K2 which is synthesized by intes-
tinal bacteria. The synthetic form of vitamin K, vitamin K3 , 
is known as menadione (Sebrell and Harris, 1954; Devlin, 
1982), (Figures IV, V, and VI). Until quite recently, the 
exact role of vitamin K in the hepatic formation of the 
active clotting factors II, VII, IX, and X was not completely 
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understood or verified. Experimentation has suggested that 
vitamin K is an essential component in the conversion of 
prothrombin from its liver precursor (Suttie, 1979). Spe-
cifically, vitamin K serves as a necessary cofactor in the 
carboxylation of the glutamic acid residues to y-carboxy-
glutamic acid in the prothrombin precursor. The y-carboxy-
glutamic acid residues of prothrombin bind Ca++. A subse-
quent reaction occurs in which the ca++_bound prothrombin 
complexes with a negatively charged phospholipid membrane 
connecting the prothrombin to thrombin when associated with 
active clotting factors V and X (Suttie, 1979; Devlin, 1982), 
(Figure TX). 
Previous Use of Heparin 
Earlier investigations in our laboratory utilized 
sodium heparin as the anticoagulant altering the fibrin 
deposition around the tumor. Sodium heparin administration 
results in a hypocoagulable state through a route quite 
different from that of warfarin sodium. The mechanism of 
action of heparin evolves around direct activity against 
thrombin formation leading to reduced conversion of fibrino-
gen to fibrin. This anticoagulant also prevents the activa-
tion of factor IX in the normal clotting design (Wormser, 
1978). Results from the studies at the University of the 
Pacific School of Pharmacy revealed a significant reduction 
of tumor growth in C3HjHeJ virgin female mice implanted 
with spontaneous tumor cells and dosed with sodium heparin. 
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These observations led to the suggestion that tumor growth 
could be reduced by alteration of the fibrin cocoon encasing 
it (Knapp et al., 1981; Banaja, 1982). 
Clinical and Experimental Investigation 
of the Relationship of Anticoagulation 
and Neoplastic Growth 
Accompanying the evolution of theories and observations 
describing the presence of a fibrin encasement around a 
tumor, several postulations pertaining to the role of a 
neoplastic fibrin cocoon have been recorded. Perhaps it is 
the fibrin encompassing metastatic tumor cells which facili-
tates their establishment (Zacharski et al., 1979). Other 
hypotheses concerning the mechanism of action of the fibrin 
cocoon propose that the role of the ~ncasement lies in 
nutrient provision or in stimulation of growth, with the 
fibrin clot as the trellis for tumor growth (Zacharski et al., 
1979). Others suggest that the cocoon may also serve as a 
protective device disguising the tumor from immune surveil-
lance of the host, or it is conceivable that a combination 
of these proposals may qualify as an explanation of the 
purpose of a tumor's fibrin encasement (Zacharski et al., 
1979). These proposals have led to further questions regard-
ing the possible role of anticoagulation in neoplastic 
management. Numerous studies have revealed that hypocoagu-
lability, induced by heparin, the oral anticoagulants, and 
ancrod (pit viper venom) may result in a decrease in tumor 
.metastasis. This decrease may also develop through hyper-
29 
fibrinolysis, induced by plasmin and urokinase. On the 
other hand, observations have shown that hypercoagulability 
and hypofibrinolysis may lead to a resultant increase in 
metastasis (Hilgard, 1976), (Figure X). These findings 
suggest the pathophysiological significance of blood coagu-
lation and also suggest a possible role of anticoagulation 
as a viable tool for neoplastic growth control. 
In their third edition Basic Pathology text Robbins, 
Angell, and Kumar (1981) reported that the tumor's fibrin 
encasement might provide protection for the tumor; however, 
they felt that little or no clinical or experimental evidence 
had been presented that would result in reduced metastases. 
Evidence linking blood coagulation changes with neoplastic 
development began to appear as early as the 1930's, with an 
increase in studies beginning in the 1960's. Preliminary 
investigations on the effect of altered blood coagulation 
dealt with animal test subjects. In 1930, Alfred Goerner 
presented the results of experiments which served as early 
hints of an interrelationship between a modification in the 
normal clotting mechanisms and a resultant change in tumor 
growth response. Goerner exposed rat carcinoma cells to 
solutions conditioned with 0.1 percent sodium oxalate in 
normal saline, 0.1 percent heparin in normal saline or normal 
saline which served as the control. Following various 
degrees of exposure to the solutions, Goerner monitored in 
vivo tumor growth finding no difference in tumor growth 
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Figu~e X. The Effect of Altered Blood Coagulability on the 
Development of.Tumor Colonies in Various Animal 
Systems. 




to the test solutions for three hours showed modest reduc-
tions in tumor growth while 22 hours of tumor cell exposure 
revealed a large reduction in tumor growth in the oxalate-
conditioned tumor fragments and no observable tumors in the 
heparin-treated group (Goerner, 1930). 
The number of studies in this field rapidly multiplied 
in the 1960's. Eugene E. Cliffton, of the Sloan-Kettering 
Institute for Cancer Research, and his associate, Domenico 
Agostino, recognizing the importance of fibrin in metastasis 
establishment, examined the effect of warfarin, heparin, and 
fibrinolysin on lung metastasis in 1965. Rats innoculated 
with untreated normal carcinoma cells showed pulmonary 
metastasis of 60 to 81 percent in a period of nine weeks. 
Tumor cells exposed to heparin and 'fibrinolysis showed a 
significant reduction in metastasis while the coumadin group 
had a reduction, but to a smaller degree. Their further 
investigations have shown varying results; however, they 
continued to point out the possibility that anticoagulants 
may be feasible aides in treating cancer (Cliffton and Agos-
tino, 1965). In 1968 findings of a significant reduction 
in metastasis in coumadin-treated mice were further substan-
tiated by the experiments of Ryan, Ketcham, and Wexler (Ryan 
et al., 1968). One year later, in 1969, Ryan demonstrated 
the effectiveness of warfarin when accompanied by removal of 
the primary seeding tumor in reducing distant metastases in 
mice (Ryan et al., 1969). 
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In 1973 Brown and associates presented experimental 
studies examining the effects of orally administered warfarin 
sodium on sarcoma cell metastasis in syngeneic C3H mice. 
Brown demonstrated that following the intravenous administra-
tion of a pre-determined number of neoplastic cells, warfarin 
anticoagulation effectively reduced the number of lung 
metastases at the very highly significant level. Examina-
tions of lung metastasis of warfarin-treated mice following 
thigh-implantations of sarcomas likewise showed some reduc-
tion in the number of developing lung colonies. Tumor cells 
possessing in vitro growth capabilities were placed in growth 
medium later conditioned with warfarin. Observations 
revealed no cytotoxic capacity until the in vitro warfarin 
sodium concentration was at a ten-fold level of the maximum 
plasma concentration of warfarin in the test animals. In 
vivo studies of leukemic cells showed no significant differ-
ence in the TD50 between the control and test animals, 
further supporting the postulations that warfarin lacks 
cytotoxic and cytostatic properties. Brown concluded that 
warfarin anticoagulation might contribute to metastasis 
reduction and that its activity was expressed through neither 
cytostatic nor cytotoxic means (Brown, 1973). 
In 1978 Adreina Poggi reported the results of a study 
in which he investigated the effect of coumadin administra-
tion upon the formation of metastatic lung colonies subse-
quent to intravenous injection or intramuscular implantation 
of syngeneic tumor cells in 350 mice. Accompanying an 
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effectively altered prothrombin time statistically signifi-
cant inhibition and reduction in primary tumor and lung 
colony development were seen yielding the conclusion that 
reduced tumor growth and metastasis are achieved thr.ough 
an impairment of the availability of vitamin K by coumadin. 
More recently, Wattenberg has conducted studies on chemically-
induced rat mammary tumors and mouse forestomach tumors and 
demonstrated some growth inhibition by coumarin (Wattenberg 
et al., 1979). In 1981 Dvorak and associates presented 
studies showing that some neoplasms may have procoagulant 
activity in vesicles shed from their membranes. It is 
proposed that these may potentiate or be responsible for 
the blood clotting activation and fibrin encasement observed 
around a neoplastic growth. This is in agreement·with 
previously documented observations of tumor-associated pro-
coagulation factor in guinea pigs and mice (Dvorak et al., 
1979 and 1981). 
Studies investigating the possibility of clinical 
applications of warfarin in cancer patients have been reported 
by several researchers, including R. Douglas Thornes of the 
Department of Experimental Medicine, Royal College of Sur-
geons, Ireland. In 1961 Thornes began examinations of the 
effective use of warfarin as an adjunct to traditional chemo-
therapeutic schedules. Using the test patients as their 
own controls, Thornes determined the level of response to 
the added warfarin by the degree the chemotherapeutic agent 
could be reduced while still holding the patient· in remission. 
! 
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Results showed response by 29 of the 96 patients and 21 
patients responded with an average reduction of 25 percent 
of the chemotherapeutic agent during a three month period. 
Thornes advocated that oral anticoagulant adjunct therapy 
be considered a viable tool in a chemotherapeutic regimen 
( Thornes, 1972) . 
Not all of the clinical investigations have shown anti-
coagulants supplementing traditional therapy to be beneficial 
in improving or prolonging cancer patient survival. In 1979 
Stanford examined patients with small cell carcinoma of the 
bronchus. Twelve of the patients received warfarin and 
heparin in conjunction with the cytotoxic drug treatment. 
Stanford found that patients in the test group had a median 
survival of 8. 85 mon.ths while those in the control group had 
a median survival of 9.71 months (p > 0.05) (Stanford, 1979). 
Thus, Stanford's conclusions contradicted Thorne's earlier 
evaluations, emphasizing the requirement for more extensive 
studies to fully evaluate the status of anticoagulants in 
cancer therapy (Stanford, 1979). 
Examination of the validity of suppl.ementing chemothera-
peutic agents and radiation treatments with warfarin sodium 
was pursued by Leo Zacharski and co-workers in a five year 
Veterans' Administration cooperative study begun in April 
1976. The four year results followed the progress of fifty 
patients positively diagnosed with small cell carcinoma of 
the lung. Twenty-five of the patients were initiated on a 
reKimen ~upplemented with warfarin sodium. Zacharski found 
results favorable to the use of warfarin. Those in the 
control group, receiving only chemotherapy and radiation 
therapy, showed a mean survival of 24 weeks; however, the 
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25 test patients who received warfarin along with their 
chemotherapeutic and radiation regimen showed a median sur-
vival of 50 weeks. Demonstrable, but not significant, dif-
ferences were found in the time until relapse in the controls 
(20.5 weeks) and the warfarin-treated patients (36.1 weeks). 
Conclusions included the suggestion that fibrin does play 
a role in tumor growth and metastasis, and the improvement 
in survival times in patients receiving warfarin intimated 
that warfarin may be beneficial in cancer therapy (Zacharski 
et al., 1979 and 1981). 
In Medical World News of March 1981, oncologist A. 
Philippe Chahinian of Mount Sinai Medical Center, New York, 
reported that the battle against tumor metastases, using 
warfarin as the primary method of attack, had only begun. 
Chahinian and the National Cancer Institute reported that 
an international cooperative study involving 28 medical 
centers was being developed to evaluate and hopefully aid 
in the confirmation of the previous studies conducted by Leo 
Zacharski. The two year study is evaluating 250 cancer 
patients, all receiving chemotherapeutic agents, half of 
whom will have their therapeutic regimen supplemented with 
warfarin. Effectiveness of warfarin will be measured on the 
basis of the time required for the detection of new metastatic 
growths. Chahinian feels that upon completion of this 
examination, the results of the Veterans' Administration 
Cooperative Study will be confirmed and warfarin will be 




It has long been agreed that tumors possess the capacity 
to induce their own vascularization (Auerbach, 1976). This 
understanding and the newly acknowledged idea that tumors 
release a vascularization-inducing factor have involved 
establishing the concept that inhibition of tumor angio-
genesis may act as a mechanism in the control of tumor 
growth. In early attempts to explain what had been observed 
with vascularized tumors, two ideas were proposed. The 
first suggested that. vessels provid~ng vascularization to 
the tumor were dilated host vessels that were normally in 
the area but which had been altered by a change in the meta-
bolic requirements of the host in response to the tumor 
(Folkman, 1976). The second proposal suggested that these 
vessels resembled those which are associated with inflamma-
tion (Folkman, 1976). These proposals were considered quite 
plausible until contributions by Greenblatt and Shubik (1968) 
and later Folkman presenting experimental evidence that tumors 
had the capability of inducing capillary proliferation in 
healthy tissue from which they were physically separated 
(Folkman, 1975 and 1976). These observations exemplified an 
evolving theory that a tumor released a humoral factor which 
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could diffuse across a physical barrier and stimulate neovas-
cularization (Folkman, 1976). A 1971 report also pointed 
out that Folkman's research team had successfully isolated a 
tumor-secreted factor, known as a tumor angiogenesis factor 
(Folkman, 1975). Folkman had found this factor successful 
in promoting vascular proliferation and capillary network 
formation both in vivo and in vitro and had shown it capable 
of inducing capillary endothelial cell mitosis (Folkman et 
al., 1975 and 1980). These breakthroughs led to the develop-
ment of the current tumor neovascularization proposal that a 
tumor is able to contribute to the formation of its own 
vascular supply by releasing a diffusible substance which 
stimulates tumor infiltration by host blood vessels (Folkman, 
1975). Furthermore, this capacity of neovascularization not 
only prOVides the tumor cells with their nece~sary n~trients 
and method of eliminating their wastes, but may also provide 
a means through which tumor growth may be controlled (Folk-
man, 1975). 
Continued experimentation in this area has provided 
new knowledge of the process which occurs during tumor vas-
cularization. Folkman and Gimbtone's study of tumor growth 
employing the rabbit cornea assay has revealed that neoplastic 
vascularization consists of two separate steps, the prevas-
cular and vascular stages (Gimbrone et al., 1974). In the 
prevascular stage the tumors grow in a thin layer expanding 
slowly; at the same time host vessels in the vicinity of the 
slowly progressing tumor begin to grow toward the tumor, 
38 
finally penetrating it. Upon host vessel penetration of the 
tumor, the vascular stage begins. At this time the tumor 
becomes well vascularized and rapidly expands (Gimbtone et 
al., 1974). These and numerous other examinations have 
demonstrated the vital role vascularization plays in trans-
forming a small dormant neoplastic mass into one which is 
potentially lethal. 
In conjunction with the tumor angiogenesis factor 
hypothesis, many researchers have suggested that an inter-
ruption of blood vessel proliferation to the tumor would 
alter tumor growth (Folkman, 1975; Maugh, 1981). The method 
by which this blockade can occur has been outlined by Folk-
man. Folkman has proposed that there are four points at 
which angiogenesis can be inhibited. These include a pos-
sible attack on the tumor cell mechanism Which produces tumor 
angiogenesis factor, resulting in reduced tumor angiogenesis 
factor production. Secondly, Folkman suggested designing 
a method of finding a substance which would prevent the 
passage of the tumor angiogenesis factor from the tumor to 
the capillary endothelial cells. A third block or obstruc-
tion would be achieved by reducing or abrogating the mitogenic 
capacity of the tumor angiogenesis factor or by prevention 
of the division of the capillary endothelial cells. Finally, 
Folkman proposed the prevention of tumor vascularization by 
preventing capillary infiltration of the tumor (Folkman, 
1974). These proposals are being exposed to careful scruti-
nization and experiments have shown that the use of angiogenesis 
inhibition in regulating tumor growth is indeed valid 
(Folkman, 1976; Maugh, 1981). 
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MATERIALS AND METHODS 
Animals 
The experimental protocol was designed to utilize 
36 virgin female C3H/HeJ mice. These animals were obtained 
from Jackson Laboratory, Bar Harbor, Maine. All mice were 
relatively identical, i.e., 3 mo. to l year in age and 
weighing from 18 to 30 grams. While at the University of 
the Pacific, all of the experimental and control mice were 
maintained in metal cages with 12 mice per cage. Bedding 
was composed of processed natural wood fiber obtained from 
K. C. Pharmacal, North Kansas City, Missouri. The mice were 
fed a high protein (not less than 20% crude protein) diet 
in pellet form manufactured by Simonsen Laboratories, Inc., 
Gilroy, California, and watered, ad libitum, upon arrival 
at UOP, with a continuance of this regimen for the duration 
of the experiment. During the experiment all of the mice 
were housed in the UOP School of Pharmacy animal wing which 
is maintained with a regular 12-hour lighting cycle with 
lights on at 6:00AM and off at 6:00PM. Temperature is 
.held within the standards recommended by the Institute of 
Laboratory Animal Resources of 18-29° C (± lOC). 
Tumor 
The tumor used for implantation into the 36 experi-
mental mice was a spontaneously developed C3HjHeJ mouse 
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mammary tumor. The tumor-donating mouse was given to our 
laboratory by Larry Young, Department of Pathology, Uni-
versity of California at Davis, School of Medicine. 
Pharmacologic Agent and 
Dosing Regimen 
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The pharmacologic agent used in this study was injected 
warfarin sodium (coumadin), purchased from Endo Laboratories 
(Garden City, New York). The anticoagulant was obtained in 
single injection units which were reconstituted, properly 
diluted and immediately injected. The crystalline warfarin 
sodium and the solutions for injection were reconstituted 
and diluted using sterile water for injection, u.s.p. 
(pH 5.0- 7.0). All solutions were thoroughly mixed before 
and after preparing the dilutions to insure that an appro-
~riat~ coricentration of the solution was obtained for further 
dilutions. Serial dilutions of the reconstituted solution 
yielded a solution of 0.75 mgjkg, high dose, and 0.15 mgjkg, 
low dose, warfarin sodium. 
The 36 animals were divided into three groups of 12 
each. Two groups of experimental C3H/HeJ virgin females 
were treated with warfarin sodium. Group A, high dose, 
received daily doses of 0.75 mgjkg i·E· warfarin sodium; 
Group B, low dose, received daily injections of 0.15 mgjkg 
!·E· warfarin sodium. A daily injection regimen was insti-
tuted five days prior to the tumor implantation with daily 
(5 PM) administration of the agent continued for the duration 
of the experiment. Animals belonging to Group C, controls, 
42 
were treated daily with sterile, nonpyrogenic lactated 
Ringer's injection, u.s.p. This regimen was initiated five 
days prior to tumor implantation and, likewise, continued 
with daily administration for the duration of the experiment. 
Upon inject~on, each animal was weighed on a top-loading 
balance and point body weight doses of the appropriate solu-
tions were injected, l·E· Injections were performed using 
disposable insulin syringes with 14.7 mm needles. Extreme 
care was taken not to puncture the bladder or the intestines 
with the injection needles. 
Animal Identification 
Each animal received an anatomical label to aid in 
accurately determining the percent of original tumor implant 
present at sacrifice. This was accomplished by swabbing. 
the appropriate area of the mouse with a saturated solution 
of picric acid. This method proved effective for identifi-
cation of individual mice in each group for the duration of 
the experiment. 
Tumor Preparation 
The animal providing the large, solid, and highly 
vascularized spontaneous C3HjHeJ tumor was sacrificed by 
overetherization in a hard plastic dessicator, adapted to 
an ether chamber for experimental purposes. The skin cover-
ing the tumor was cleansed with alcohol to prevent hair 
from contaminating the surgical field. A postmortera.dis-
section of the tumor area was performed with autoclaved 
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surgical instruments; removal of the overlying skin exposed 
the tumor. The tumor mass was excised and large sections 
were placed in petri dishes filled with cold lactated Ringer's 
solution. Using sterile surgical instruments, the tumor 
pieces w·ere washed in the cold Ringer's and placed in clean 
Ringer's solution for sectioning. Working quickly to insure 
maximum tumor cell viability, cleaned tumor pieces were 
further cut into sections 0.0114 ± 0.00035 grams (mean ± SEM) 
in size. The transplantation-size tumor pieces were trans-
ferred into fresh Ringer's solution for subsequent implanta-
tion into the experimental and control animals. 
Tumor Implantation 
At time zero, all 36 animals received finely minceq 
subcutaneous implants of C3HjHeJ spontaneous mouse mammary 
tumor 0.0114 ± 0.00035 grams (mean± SEM). The following 
procedure was employed for each mouse in the experiment: 
l. the mouse was lightly anesthetized in an ether 
chamber; 
2. in preparation for tumor implantation, an indi-
vidual piece of sectioned spontaneous mouse mammary 
tumor was weighed and the weight recorded. As 
noted earlier, each mouse was labeled for future 
reference as to tumor implant weight; 
3. the anesthetized mouse was placed on a dissection 
board and held by the tail and the nape of the 
neck, slightly stretching the dorsal skin, while 
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leaving the dorsal surface exposed. The skin over-
lying the base of the tail on the dorsum was rinsed 
with alcohol and a l/4" incision was cut with 
scissors through the skin; 
4. a 13-gauge wide-bore trocar, loaded with a pre-
viously weighed tumor, was inserted through the 
incision and the end guided to the dorsal side 
of the left shoulder;. 
5. following placement of the trocar in the desired 
location a rod was inserted inside the barrel of 
the trocar, expelling the tumor implant at the 
desired site caudally to the left shoulder; 
6. the trocar was withdrawn and the incision pinched 
closed. The entire i~plantation pr6cedure involves 
only approximately 15 seconds for each mouse. 
No problems with infections have been experienced. Following 
each implantation, the animals were placed in a separate cage 
and observed until they had recovered from the procedure. 
Experimental Schedule 
A synopsis of the experimental schedule is presented in 
Table l. The experiment began five days prior to tumor 
implantation with the initiation of the drug administration, 
as discussed previously. On day 0, all 36 of the experi-
mental and control mice were implanted with pre-weighed 
spontaneous C3H/HeJ mouse mammary tumor pieces. Twenty-four 




Implantation CONTROL A B 
(T = 0 hr.) Ringer's Warfarin Warfarin 
Sodium Sodium 
High Dose Low Dose 
(N = 12) (N = 12) (N = 12) 
Sacrifice 
1 day 3* 3 3 
2 day 3 .. 3 3 
4 day 3 3 3 
8 day 3 3 3 
*Indicates the number of mice sacrificed at each day. 
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experimental group were sacrificed. This procedure was 
repeated on day 2, day 4, and day 8. 
$acrifice Protocol 
At each indicated sacrifice time, several observations 
and examinations were performed. These included: a deter-
mination of whole blood clotting times; sacrifice of each 
animal; photography of each tumor; rating of local vascu-
larity, vasodilation and edema fluid; and the extent of 
tumor attachment. The tumors were excised, weighed, and 
placed in formalin for fixation. 
Whole Blood Clotting Time 
Determinations 
Prior to sacrifice, the whole blood clotting time was 
determined for each mouse using the Le~ White whole blood 
clotting time method (Vigran, 1965). The mice were lightly 
anesthetized with diethyl ether. Using non-heparinized 
microhematocrit capillary tubes, a periorbital puncture was 
performed and one tube (0.7 cc) of whole blood collected. A 
stopwatch recorded the time the blood entered the capillary 
tube and was kept running until a clot had formed. Clot 
formation was observed by tilting the capillary tube, end 
to end, every thirty seconds. When the blood ceased flowing 
scores were made in the capillary tube and it was broken 
every thirty seconds until a clot had formed and stretched 
across the break in the capillary tube. This time was 
recorded as the whole blood clotting time. 
Sacrifice and Macroscopic 
Evaluations 
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Following the whole blood clotting time determination, 
the mice were sacrificed by overetherization. The mice were 
placed on dissection boards and their dorsal sides were 
washed with alcohol to prevent hair from entering the field. 
A midline dorsal incision was performed and the dorsal skin 
pinned back to expose the tumor. The superior epigastric 
and external thoracic veins and their branches were examined 
on the tumor side and the opposite side of the mouse to 
determine the presence or absence of vasodilation. Vascu-
larity in the area of the tumor was determined by counting 
the number of vessels approaching the tumor. The criteria 
for the vascularity ratings are presented in Table II. The 
immediate vicinity of the tumor was examined for the presence 
or absence of local edema fluid. Each tumor and its sur-
roundings were photographed with a 50 mm macro lens to allow 
later observations and for illustrative purposes. The final 
procedures involved excising each tumor, observing and 
rating the extent of attachment, as illustrated in Table III, 
and weighing the tumor. Following weight determination each 
tumor was fixed in formalin. 
Statistics 
The percent of the original tumor mass present at sac-
rifice was calculated by dividing the tumor sacrifice weight 
by the tumor implant weight and multiplying by one hundred. 





Table I I 
Rating Criteria for Vascularity 
in the Locale of Tumor 
No; No Vessels Present 
+· 
' Vessels in the area 
++; Countable ( < 5) to tumor 







Attachment of Tumor Rating Criteria 




++; cut out 
+++; cut out leaving gouge in skin 
Edema Flu~d & Local Vasodilation 
Evaluation 
Present or Absent 
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vascularity and attachment ratings were evaluated for sig-
nificance between the means by the Dunnett's t test. Evalu-
ations of the presence or absence of edema fluid and local 
vasodilation were inspected for significance between the 
control and each warfarin sodium group by employing the Chi-
Square test for significance between two groups of quantal 
data. All means were reported ± 1 standard error of the 
mean. 
RESULTS 
1. Whole Blood Clotting Time 
Intraperitoneal injection of high dose, 0.75 mgfkg, 
warfarin sodium in Group A was associated with a significant 
prolongation (p < 0.05) in whole blood clotting time in 
comparison to the control group (Table IV, Figure XI). Mice 
receiving 0.75 mgjkg warfarin sodium had a mean clotting 
time of 392.7 ± 16.9 seconds, whereas those mice receiving 
daily injections of lactated Ringer's solution exhibited mean 
clotting times of 161.4 ± 26.7 seconds. The mice in Group B, 
0.15 mgjkg (low dose), warfarin sodium also showed a pro-
longed clotting time with respect to those in the control 
group. This prolongation was not statistically significant. 
The mean whole blood clotting time for Group B mice was 
228.9 ± 33.7 seconds (Table IV, Figure XI). 
2. Tumor Weight 
Animals in the high dose, 0.75 mgjkg, warfarin sodium 
group showed a significantly reduced (p < 0.05) percent of 
original tumor weight upon sacrifice when compared to the 
mean percent of original tumor weight in the control group 
at sacrifice. The mean percent of original tumor weight in 
Group A at sacrifice was 30.67 ± 4.75 percent. Those mice 
receiving low dose warfarin sodium showed a nonsignificant 
trend towards a reduction in percent of original tumor weight 
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Table IV 
Summary of mean tumor implant weights (in grams), whole blood clotting times 
(monitored in seconds), and the percent of the original tumor weight as 
observed in the high dose (0.75 mgjkg), low dose (0.15 mgjkg) warfarin 













0.0127 ± 0.00062a,* 
392.7 ± 16.9 
30.67 ± 4.75 
Group B 
Low Dose 
0.0106 ± 0.00050 
228.9 ± 33.7 
43.08 ± 2.70 
Control 
Group C 
0.0109 ± 0.00056 
161.4 ± 26.7 
58.98 ± 8.72 
aN = 12 for all except High Dose Warfarin Sodium Whole Blood Clotting Time 
with N = ll. 
*Mean ± S.E.M. 
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when compared to the control group. The mean percent of 
original tumor weight observed in Group B at sacrifice was 
calculated as 43.08 ± 2.70 percent. Mice dosed with Ringer's 
solution, the control group, demonstrated a mean of 58.98 ± 
8.72 percent of the original tumor mass on the sacrifice 
days (Table IV, Figure XII). 
3. Vascularity in the Locale of the Tumor 
Mice receiving 0.75 mgjkg warfarin sodium exhibited a 
significant (p < 0.05) reduction in the amount of vascu-
larity in the locale of the tumor. Vascularity ratings for 
this group were 1.90 ± 0.314 while the mean vascularity 
rating for the control mice was 3.42 ± 0.229. Group B, low 
dose warfarin sodium, showed a minimal, but not significant, 
reduction in tumor vascularity with a mean rating of 2.00 ± 
0.302 (Table V, Figure XIV). 
4. Tumor Attachment 
Tumor attachment was found to be significantly reduced 
(p < 0.05) in both the high and low dose warfarin sodium 
groups. The high dose warfarin sodium group demonstrated 
a mean tumor attachment rating of 1.67 ± 0.284 while those 
mice in the low dose warfarin sodium group had a mean tumor 
attachment rating of 2.75 ± 0.250. Mice in the control 
group demonstrated a mean attachment rating of 3.67 ± 0.142 
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Table V 
Vascularity and attachment evaluations, observed in high dose (0.75 mgjkg) 
and low dose (0.15 mgjkg) warfarin sodium and control groups 
:warfarin Sodium Control 
-~ - -~------- ------ -
Parameter 
Investigated High Dose Low Dose 
Local Vascularity 1.90 ± 0.314a,* 3.00 ± 0.302 3.42 ± 0.229 
Rating 
Attachment Rating 1.67 ± 0.284 2.75 ± 0.250 3.67 ± 0.142 
aAll N = 12 except High Dose Warfarin,Sodium vascular rating with N = 10. 
*Mean ± S.E.M. 




~ .... .... .... 
~ .... 
'.. <( .... .... .... 








. . .. 
<( m 
.... 
~ .... .... 























































5. Local Vasodilation 
Local vasodilation evaluations revealed a significant 
reduction (p < 0.025) in vasodilation of vessels near the 
tumor in group A, with only 50% of these mice showing the 
presence of vasodilation. A trend towards a reduction (not 
significant) in vasodilation was seen in the low dose war-
farin sodium group. Eleven of twelve or 92% of the mice 
in the low dose group demonstrated local vasodilation. 
All mice in the control group showed local vasodilation 
(Table VI). 
6. Edema Fluid 
Evaluations of the presence or absence of edema fluid 
around the tumor again demonstrated a significant reduc~ion 
(p < 0.01) in edema fluid in the mice treatedwitha high 
dose of warfarin sodium. Only 30% of the tumors in this 
group had edema fluid around the tumor. Again, only a mini-
mal nonsignificant reduction in edema fluid was seen in the 
low dose warfarin sodium group with 92% of the tumors having 
edema fluid. The control mice demonstrated the presence of 
edema fluid in 100% of the mice (Table VII). 
Table VI 
Local vasodilation ratings in high dose (0.75 mgjkg), 
low dose (0.15 mgjkg) warfarin sodium and control 
groups evaluated as a ratio of the number of 
positive responses to the total 


















Edema fluid ratings in high dose (0.75 mgjkg), 
low dose (0.15 mgjkg) warfarin sodium and 
control groups evaluated as a ratio of 
the number of positive observations 


















This study has shown that there is a significant reduc-
tion in the percent of original tumor mass compared to 
control animal tumor growth when warfarin sodium is admin-
istered at a dose of 0.75 mgjkg. Reductions were also noted 
in the group receiving low dose (0.15 mgjkg) warfarin sodium; 
however, these reductions were not significantly different 
from the control group. Observations of the low and high 
dose warfarin sodium groups showed a trend towards a reduc-
tion in all of the variables examined in the low dose group 
and an even greater reduction in the tumor weight, vascular-
ity, and attachment parameters in the high dose group. Dose-
response ~orrelations can be suggested which relate the 
alteration of vascularization and tumor growth in the test 
animals. 
Our experiments demonstrated that with the daily 
administration of a high dose of warfarin sodium (0.75 mgjkg) 
significant reductions in tumor growth could be observed 
(Table IV, Figure XII). It has been postulated by other 
workers that an induction of a state of anticoagulation 
would reduce the amount of tumor growth through a reduction 
in the tumor's fibrin encasement (Lock, 1971; Zacharski et 
al., 1979; Brown, 1973). This idea has also been demonstrated 
in previous studies conducted by Brown and Zacharski (Brown, 
1973; Zacharski et al., 1979, 1981). 
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Several factors must be considered when speculating why 
an alteration in fibrin investment of a tumor may lead to 
reduced tumor growth. It is conceivable that the reduction 
in tumor growth is not attributable to the altered fibrin 
formation, but the reduced tumor growth is due to warfarin's 
cytotoxic effects upon the tumor cells (Thornes, 1972). 
Although a plausible explanation, J. Martin Brown demon-
strated that warfarin possessed no cytotoxic activity towards 
KHT cells in vitro (Brown, 1973). Previous studies using 
sodium heparin in C3H/HeJ mice noted mammary tumor growth 
reduction in anticoagulated animals (Knapp et al., 1981). 
Since heparin anticoagulates by a mechanism different from 
warfarin, those results in conjunction with ours suggest 
that the"anticoagulation is affecting tumor growth rather 
than acting through a cytotoxic mechanism upon the tumor 
cells. 
This coat removal or reduction may lead to a variety 
of situations in which the tumor has reduced capacity to 
grow. Some researchers believe the fibrin encasement pro-
vides a physical barrier, c9ncealing the developing tumor 
from the host's immune surveillance (Dvorak et al., 1979, 
1981). Specifically, the fibrin coat may shield the tumor-
specific transplantation antigens from detection by the 
host's immune system. The fibrin coat may prevent lympho-
cytes, involved in tumor surveillance, from reaching the tumor 
(Dvorak et al., 1979, 1981). If the fibrin encasement is 
not surrounding the tumor then it is possible that the tumor 
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could be detected by the host; the tumor-specific transplan-
tation antigens may be detected by the host's lymphatic 
system; and activated lymphocytes would have easier accessi-
bility to the tumor. An appropriate step in experimental 
studies would be an investigation of the leukocytic infil-
trate around the tumor at sacrifice. This, however, was not 
investigated in this experiment. 
Suggestions have also been made that the fibrin deposi-
tion plays both a nutritional role and a structural role 
(Dvorak et al., 1979a; Zacharski et al., 1979). Absence of 
the fibrin could result in the inability to maintain adequate 
nutrition and lack of a framework upon which tumor cells can 
grow. Fibrin formation and neovascularization have been 
closely associated, and an alteration in fibrin cocoon forma-
tion may effectively change tumor vascularization and conse-
quently growth (Lock, 1971; Dvorak et al., 1979a). Our 
results confirm a concomitant reduction in both tumor growth 
and vascularization with warfarin, further supporting evidence 
of a relationship between the two factors. 
The suggestions that warfarin's anticoagulative activity 
and resultant reduction in fibrin formation is the mechanism 
causing reduced tumor growth could be further investigated 
through the concurrent administration of warfarin and vita-
min K. In this situation, vitamin K would counteract war-
farin's activity and allow adequate clotting protein synthesis 
for the ultimate development of fibrin. It would be expected 
that warfarin sodium administration, accompanied by vitamin K, 
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would permit fibrin encasement of the tumor and growth com-
parable to tumor growth in control animals. This hypothesis 
has been tested by Brown using mice and examining tumor lung 
colony development. Results of Brown's experiments demon-
strated that mice receiving both warfarin and vitamin K had 
no prolongation in prothrombin time and no reduction in 
tumor lung colony formation (Brown, 1973). 
The animals receiving low doses, 0.15 mgjkg, warfarin 
sodium, exhibited intermediate values in whole blood clotting 
time, the percent of original tumor mass, local vascularity, 
vasodilation in the locale of the tumor, edema fluid, and 
tumor attachment (Tables IV, V, VI and VII; Figures XII, 
XIII, XIV). These observations suggested a dose-response 
relationship between warfarin and tumor growth and other 
related factors. In animals which received high dos~ war-
farin sodium, a more substantial level of anticoagulation was 
achieved (Table IV, Figure XI). If a dose-response relation-
ship may be suggested, the higher level of anticoagulation 
would result in a greater inhibition of fibrin formation and 
tumor investment. In the animals dosed with 0.15 mgjkg 
warfarin sodium, reductions in tumor growth and related 
factors were observed to a lesser degree than in the high 
dose animals. · These findings suggest that an intermediate 
level of anticoagulation provided only a moderate decrease 
in fibrin encasement of the tumor. 
Observations in the animals receiving high doses of 
warfarin sodium also revealed a significant reduction in the 
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number of host blood vessels converging on the tumor and 
also in vasodilation in the locale of the tumor (Table V, 
Figure XIV). Trends towards a reduction in vascularity, 
which were not significant, were observed in the low dose 
warfarin sodium group; and 92 percent of the animals in this 
group showed the presence of vasod~lation. Again, these 
findings suggest both a dose-response relationship and a 
link between tumor vascularization and tumor growth. Earlier 
studies have suggested that vascularization of the tumor is 
required for adequate nutritional maintenance and waste 
disposal (Folkman, 1976; Gullino, 1978, 1981; Maugh, 1981). 
Folkman has demonstrated that the absence of a blood supply 
results in an abrupt cessation of tumor growth, leaving a 
small dormant tumor mass ( 1976). It has previo·usly been 
suggested that the induction of anticoagulation results in 
the reduction of tumor encasement by fibrin: Dvorak has 
linked the fibrin cocoon with neovascularization, stating 
that vascular changes have been associated with fibrin cocoon 
investment in line 10 guinea pig carcinomas (1979a). An 
editorial in the British Medical Journal has proposed that 
the fibrin coat may possess angiogenesis-inductive capabili-
ties (Lock, 1971). Our findings are in agreement with these 
many studies and lend evidence that the reduced fibrin coat 
has potentiated a reduction in tumor vascularization. 
As mentioned earlier, vascularization is necessary for 
the advancement of a tumor mass from a dormant state to one 
of progressive growth (Folkman, 1976). The link between the 
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degree of inhibition of vascularity and reduced tumor growth 
is quite evident in the experiment presented. The animals 
which demonstrated greater reductions in tumor growth, those 
of the high dose warfarin sodium group, had significant 
reductions in tumor vascularity and local vasodilation 
(Tables V, VI; Figure XIV). It is possible that reduced 
fibrin cocoon hindered the tumor's ability to stimulate and 
incorporate host blood vessels to meet its metabolic require-
ments. The reduced tumor growth, therefore, could be attri-
buted to either the host's ability to recognize and attack 
the tumor or the failure of adequate vascularization to the 
tumor. A combination of these two mechanisms is also a 
feasible postulation. Mice anticoagulated with.a low dose 
of warfarin sodium were found to have some reduction in both 
tumor growth and vascularity. The vascularity reduction was 
not significant (Table V, Figure XIV). Perhaps the moderate 
tumor growth reduction may be linked to the moderate reduc-
tion of vessel proliferation in the area of the tumor. In 
this case, the tumor may have been able to meet some of its 
metabolic needs through the minimal vasculature provided. 
Statistically significant reductions in the degree of 
attachment of the tumor were observed in the mice in both 
the high dose and low dose warfarin sodium groups (Table V, 
Figure XIII). Again, the low dose warfarin sodium animals 
demonstrated an intermediate level of attachment reduction. 
One suggestion of the role of the fibrin cocoon has been 
in the promotion of metastasis by providing assistance in 
the lodgement of metastasizing cells (Hagmar and Boeryd, 
1969; Brown, 1973; Zacharski et al., 1979). Experimental 
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and clinical examinations of certain mouse and human tumors 
have demonstrated that the administration of agents with . 
anticoagulant activity can greatly reduce metastasis (Hag-
mar and Boeryd, 1969; Brown, 1973; Zacharski et al., 1981). 
In our examinations a demonstration of anticoagulation accom-
panied by a significant reduction in tumor attachment is 
seen. This may serve as further evidence that a reduction· 
in fibrin formation around the tumor has occurred in the 
anticoagulated animals. It may also provide supporting 
evidence that fibrin deposition may indeed be important in 
aiding the attachment of metastasizing tumor cells. 
Examination of whole blood clotting _times reveals a 
large amount of variability in clotting times; yet, the high 
dose warfarin sodium animals still show a significant pro-
longation in whole blood clotting times (Table IV, Figure XI). 
This phenomenon is not unique to this experiment. There 
have been other reports of the inability to maintain a 
steady serum level of this anticoagulant (Brown, 1973). This 
is further confirmed by several researchers investigating 
warfarin sodium activity in mice and rats (Niedner, 1974, 
1974a, 1974b; personal communications with Gerhard Levy). 
Similar findings have been seen in earlier unpublished 
observations in our laboratory. 
CONCLUSION 
From this study it has been observed that daily admin-
istration of· high doses of warfarin sodium in C3H/HeJ 
female mice with mammary tumor implants leads to a statis-
tically significant prolongation in whole blood clotting 
times. This extended clotting time is accompanied by a 
statistically significant reduction in the percent of origi-
nal tumor mas·s implanted when compared to control animals. 
Likewise, significant reductions in local vascularity, 
vasodilation, tumor attachment and edema fluid were noted 
in the high dose experimental group. These observations 
have supported the postulation that tumor growth may be 
effectively altered by decreasing fibrin formation. 
Moderate reductions, lacking statistical significance, 
were seen in the tumor growth of mice receiving low doses 
of warfarin sodium. Similarly, edema fluid, vasodilation, 
and the number of blood vessels approaching the tumor showed 
intermediate, and in some instances, significant reduction, 
values in these mice. The intermediate values suggest that 
a dose-response relationship exists between warfarin and 
the tumor-related parameters. An examination of the sig-
nificantly reduced attachment ratings observed in both of 
the anticoagulated groups suggest that defibrination may 
serve as a mechanism in the regulation of tumor metastasis 
(Hagmar, 1969; Brown, 1973; Zacharski, 1979). 
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Relationships between altered fibrin formation around 
the tumor, anticoagulant administration, and vascularization 
may serve to demonstrate a single major conclusion. Our 
experimental observations support the suggestion that the 
fibrin investment serves an important role in the establish-
ment of a vascular supply to the tumor which is vital for 
its establishment, survival, and growth. 
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